Unlock instant, AI-driven research and patent intelligence for your innovation.

Adjuvant cancer therapy

A technology for cancer and therapy, applied in the field of anti-angiogenic agents in adjuvant cancer therapy, which can solve the problems of long-term treatment, quality of life, major toxicity, and inability to distinguish tumor cells

Inactive Publication Date: 2012-05-16
GENENTECH INC +1
View PDF53 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] Despite the well-established benefits of chemotherapy-based adjuvant therapy, one major limitation associated with chemotherapy of any kind is significant toxicity
In general, chemotherapy drugs do not target the tumor site and cannot distinguish between normal and tumor cells
Toxicity issues are especially challenging in an adjuvant setting due to lengthy treatment and its lasting impact on patient quality of life

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Adjuvant cancer therapy
  • Adjuvant cancer therapy
  • Adjuvant cancer therapy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0278] Example 1: Adjuvant Bevacizumab Therapy in Patients with Colorectal Cancer

[0279] This example focuses on the analysis of results obtained from colorectal cancer subjects treated in the National Surgical Adjuvant Breast and Bowel Program (NSABP C-08) clinical trial. The primary objective of the study was to determine the clinical benefit of adding bevacizumab to standard chemotherapy used to treat colorectal cancer, as measured by disease-free survival (DFS). A secondary objective was to determine whether there was a clinical benefit in prolonging overall survival. The standard chemotherapy used in this trial was a combination of folinic acid, 5-fluorouracil, and oxaliplatin. This trial evaluates bevacizumab Efficacy as adjuvant therapy in patients with resected stage II and III colon cancer.

[0280] Research design

[0281] The design of the NSABP C-08 study is depicted in figure 1 with 2 .

[0282] In the NSABP C-08 trial, the following regimens were used: ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Disclosed herein are methods and compostions comprising anti-VEGF antibodies for use in adjuvant cancer therapy.

Description

[0001] related application [0002] This application claims U.S. Provisional Application No. 61 / 171,008, filed April 20, 2009; U.S. Provisional Application No. 61 / 171,318, filed April 21, 2009; and U.S. Provisional Application No. Priority and benefit of .61 / 181,195, each of which is incorporated herein by reference. field of invention [0003] In general, the present invention relates to the treatment of human diseases and pathological conditions. More specifically, the invention relates to the use of anti-angiogenic agents in adjuvant cancer therapy. Background of the invention [0004] Cancer is one of the deadliest threats to human health. In the United States alone, cancer affects nearly 1.3 million new patients each year and is the second leading cause of death after cardiovascular disease, accounting for approximately 1 in 4 deaths. Solid tumors are responsible for most of those deaths. Although significant advances have been made in the medical treatment of certa...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/395
CPCA61K2039/545C07K16/22A61K2039/505A61P35/00A61P35/02A61K39/395A61K39/39
Inventor G.法伊夫E.赫德里克R.D.马斯N.沃尔马克
Owner GENENTECH INC